Vol. 4 No. 5 (2024): May
Reimbursement Recommendations

Infliximab (Remsima SC)

decorative image of the issue cover

Published May 9, 2024

Key Messages

  • We recommend that Remsima SC be reimbursed by public drug plans as maintenance treatment for adults with moderately to severely active Crohn disease (CD) whose disease has had an inadequate response, or who were intolerant to, conventional therapy if certain conditions are met.
  • Remsima SC maintenance treatment should only be covered to treat adults with moderately to severely active CD whose disease had an inadequate response, or who are intolerant, to conventional therapy. Patients are required to achieve a clinical response to induction therapy with infliximab IV at week 10 of treatment to continue with Remsima SC as maintenance therapy.
  • Remsima SC should only be reimbursed if prescribed by a physician experienced in diagnosing and managing CD and should not be combined with a biologic or Janus kinase (JAK inhibitor) treatment for CD. The cost of Remsima SC should not exceed the drug program cost of treatment with the least costly biologic therapy reimbursed for the treatment of CD.